Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHMI-trans2: Malaria Transmission Model
NCT03454048Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of piperaquine in malaria (4 cohorts), sponsored by Radboud University Medical Center. Primary endpoints: Frequency of Adverse Events in the CHMI-trans Model, Gametocyte Prevalence and 1 more. Started May 2018; status: completed.
02
Drugs
piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03454048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454048.